Moat Biotechnology has created a novel second-generation single cycle-adenovirus vaccine platform technology (SC-AdVax) licensed from Mayo Clinic for the rapid development of nasal/oral vaccines for multiple infectious disease targets and cancer.
Why we invested:
Moat Biotechnology is targeting the recognized need for an intranasal vaccine for COVID-19 and other respiratory diseases. By encountering respiratory viruses at the nasal passage, it will be possible to significantly reduce their ability to replicate systemically within the body, where more serious viral morbidities occur.
Founder & Team
CEO Scott Rollins, PhD and COO Russell Rother, PhD invented Soliris, which was eventually sold to Astra Zeneca for $38 billion. They co-founded Selexys, which was sold to Novartis for $665 million. They are currently CEO and COO, respectively, of Tetherex Pharmaceuticals, from which Moat Biotechnology was recently spun out as a separate company.